Pure Financial Advisors LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Pure Financial Advisors LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 522 shares of the medical research company’s stock after purchasing an additional 112 shares during the period. Pure Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $288,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Summa Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $418,000. Private Wealth Management Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $110,000. Brookstone Capital Management grew its position in shares of Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after buying an additional 3,142 shares during the last quarter. Y.D. More Investments Ltd grew its position in shares of Thermo Fisher Scientific by 33.9% in the 4th quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock worth $207,000 after buying an additional 99 shares during the last quarter. Finally, Private Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock worth $45,187,000 after buying an additional 815 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,084 shares of company stock worth $19,767,092. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 0.0 %

Shares of TMO stock traded up $0.29 during mid-day trading on Friday, hitting $603.98. The company’s stock had a trading volume of 1,076,197 shares, compared to its average volume of 1,714,754. The stock has a market cap of $230.72 billion, a price-to-earnings ratio of 38.74, a PEG ratio of 2.80 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $622.30. The business has a 50-day moving average price of $570.86 and a 200 day moving average price of $571.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.15 earnings per share. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.71 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analyst Ratings Changes

TMO has been the topic of several research reports. Deutsche Bank Aktiengesellschaft lifted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Finally, Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $618.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.